Christophe Arbet-Engels Takes the Helm at Altimmune
Altimmune, Inc. (NASDAQ: ALT), a biopharmaceutical company advancing innovative peptide-based therapies for liver and cardiometabolic diseases, has announced a significant leadership change. The company has appointed Christophe Arbet-Engels, MD, PhD, as its Chief Medical Officer. This strategic move positions Altimmune to enhance the clinical development phase of its flagship drug, pemvidutide.
Expertise in Clinical Development
Dr. Arbet-Engels comes to Altimmune with over three decades of extensive experience in the medical field, including positions in both academia and industry. His deep knowledge of late-stage development and regulatory processes will be instrumental as he leads the upcoming Phase 3 trial of pemvidutide, specifically targeting metabolic dysfunction-associated steatohepatitis (MASH).
Leadership Transition at Altimmune
Dr. Arbet-Engels succeeds Dr. Scott Harris, who has played a critical role in advancing pemvidutide through various clinical milestones and IND submissions. While Dr. Harris plans to retire, he will continue to support Altimmune as a Senior Strategic Advisor through February 2026, ensuring a smooth transition.
The Potential of Pemvidutide
Pemvidutide stands out as a promising dual receptor agonist with the potential to deliver a new standard in treating MASH and related disorders like Alcohol Use Disorder (AUD) and Alcohol-associated Liver Disease (ALD). Dr. Arbet-Engels expresses enthusiasm about leading the development of pemvidutide, which has showcased a compelling profile in preliminary studies.
Key Developments on the Horizon
With the impending release of 48-week trial data from the IMPACT trial concerning MASH, expectations are high for pemvidutide. The ongoing Phase 2 trials for AUD and ALD further bolster its status as a transformative treatment option, capable of addressing significant unmet medical needs in these prevalent conditions.
Dr. Arbet-Engels' Background and Contributions
Before joining Altimmune, Dr. Arbet-Engels served as Chief Medical Officer at X4 Pharmaceuticals (NASDAQ: XFOR), where he made significant contributions to the successful regulatory approval of mavorixafor in WHIM Syndrome. His career includes leadership roles at several reputable organizations, playing critical roles in bringing various therapies to market. His rich background spans leadership in clinical development and regulatory navigation, making him a valuable asset to Altimmune.
Inducement Grant Details
As part of his appointment, Dr. Arbet-Engels is set to receive options to purchase 450,000 shares of Altimmune's common stock and 150,000 restricted stock units (RSUs). These incentives highlight the company's commitment to attracting top talent in the competitive biopharmaceutical landscape.
About Altimmune
Altimmune specializes in developing novel peptide-based therapeutics aimed at transforming care for patients with liver and cardiometabolic diseases. Its lead candidate, pemvidutide, is under clinical investigation for multiple conditions, showcasing Altimmune's ambition to innovate in healthcare.
Frequently Asked Questions
Who is Christophe Arbet-Engels?
Christophe Arbet-Engels, MD, PhD, is the newly appointed Chief Medical Officer of Altimmune, bringing over 30 years of clinical experience.
What is pemvidutide?
Pemvidutide is a dual receptor agonist undergoing clinical trials for the treatment of MASH, AUD, and ALD.
What role did Scott Harris play at Altimmune?
Scott Harris previously served as CMO, leading the pemvidutide program and will continue as Senior Strategic Advisor after his retirement.
What therapeutic areas does Altimmune focus on?
Altimmune is focused on developing innovative treatments for liver and cardiometabolic diseases.
Why is pemvidutide significant for future treatments?
Pemvidutide has potential to significantly improve treatment outcomes in several prevalent liver diseases, indicating its disruptiveness in the market.
